Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm 2011 Aug;19(4):286-92
Date
07/21/2011Pubmed ID
21770809DOI
10.3109/09273948.2011.580072Scopus ID
2-s2.0-79960672974 (requires institutional sign-in at Scopus site) 39 CitationsAbstract
PURPOSE: To compare the frequencies of attacks before and after immunomodulatory therapy (IMT) with mycophenolate mofetil (MMF) in recurrent punctate inner choroidopathy (PIC) and to report fundus autofluorescence (FAF) findings.
METHODS: Eight patients who had at least two recurrent episodes of increased activity before MMF and 12 months of documented clinical course before and after MMF were included. The frequencies of attacks before and after MMF were compared. FAF images evaluated.
RESULTS: Before MMF, the 8 patients experienced 19 attacks of recurrent disease activity; during MMF therapy, 3 (38%) patients experienced 6 recurrent episodes. The attack frequencies were 1.09 ± 0.75 before and 0.23 ± 0.32 during treatment (p = .036). Among the 6 patients who had FAF, surrounding hyperautofluorescent halo was detected in 4 and recurrence occurred in 2 who did not show any changes on the intensity during treatment.
CONCLUSION: In the index study, the employment of MMF has decreased frequency of attacks in recurrent PIC. FAF may be employed to monitor and predict the response to treatment.
Author List
Turkcuoglu P, Chang PY, Rentiya ZS, Channa R, Ibrahim M, Hatef E, Sophie R, Sadaka A, Wang J, Sepah YJ, Do DV, Foster CS, Nguyen QDMESH terms used to index this publication - Major topics in bold
AdultChoroid Diseases
Female
Fluorescence
Fundus Oculi
Humans
Immunologic Factors
Male
Middle Aged
Mycophenolic Acid
Recurrence
Retrospective Studies
Young Adult
